Among the identified genes, tumor-associated macrophages (TAMs) signature gene-CCL2 was increased in TGCT and the fold difference was the most significant in both 2 data sets as shown in Figure 3B and C. Therefore, we chose to focus on CCL2 as a potential TGCT gene biomarker for further study. This evidence concerns the gene CCL2 and neoplasm.